Influenza virus Hemagglutinin and Neuraminidase (HA/NA)

Influenza Hemagglutinin (HA) and Neuraminidase (NA) are the two primary surface glycoproteins found on Influenza A and B viruses, including the 2009 pandemic H1N1 (pdm09) strain (UniProt: P03468, P03469). Hemagglutinin functions as a lectin that mediates viral attachment to sialic acid receptors on host respiratory cells and facilitates the fusion of the viral envelope with the endosomal membrane (PubMed: PMC3063653). Neuraminidase is a sialidase enzyme that cleaves terminal sialic acid residues from glycoproteins, a process essential for the release of progeny virions from infected cells and the prevention of viral aggregation (CDC: Influenza Antiviral Medications). These proteins are critical therapeutic targets; HA is the primary antigen in influenza vaccines, while NA is the target of several antiviral drugs such as oseltamivir and zanamivir. The high rate of mutation in these proteins, known as antigenic drift, necessitates the frequent updating of vaccines and constant monitoring for drug resistance. The input string provided appears to be a malformed concatenation of these targets often found in vaccine or clinical trial databases.

Other names

HemagglutininNeuraminidaseHANASialidaseInfluenza A HA/NAInfluenza B HA/NApdm09 HA/NASurface glycoproteins

Neuraminidase inhibitors prevent the cleavage of sialic acid residues, thereby trapping newly formed virions on the host cell surface and preventing further spread. Hemagglutinin-targeted agents, such as vaccine-induced antibodies or fusion inhibitors, block the virus from binding to host receptors or prevent the conformational change required for viral-host membrane fusion.